Abraxane facts - Freebase

Facts from the Community

From the BioVenturist base

Indication or disease:

Disease	Phase of development	Notes
Metastatic Breast Cancer	On the market	For the treatment of patients with breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy, with prior therapy including an anthracycline unless clinically contraindicated.
Non-Small Cell Lung Carcinoma	Phase III Clinical Trial
Ovarian cancer	Phase III Clinical Trial
Melanoma	Phase III Clinical Trial
Prostate cancer	Phase III Clinical Trial
Head and neck cancer	Phase II Clinical Trial
Pancreatic cancer	Phase III Clinical Trial

View entire collection »

therapeutic molecule:

Paclitaxel

Delivery Technology:

Protein Conjugation

Technology involved:

View entire collection »

Sales:

Amount	Currency	Year	Area	Company Reporting
324,692	US$	2007	World Wide	Abraxis BioScience, Inc.
174,906	US$	2006	World Wide	Abraxis BioScience, Inc.
133,731	US$	2005	World Wide	Abraxis BioScience, Inc.

View entire collection »

Developed by:

Abraxis BioScience, Inc.

Stage of development:

On the market

top ↑

You can help improve this topic by adding more facts here

Edit this topic

Last edited Jan 16, 2009 See all topic history »

Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Flag this Topic

Why do you want to flag this topic?

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution